Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Warticon Solution

Active Ingredient:
About Medicine
{healthcare_pro_orange} This information is for use by healthcare professionals
Last updated on emc: 01 Jul 2020
1. Name of the medicinal product


2. Qualitative and quantitative composition

Podophyllotoxin 5 mg/ml (0.5% w/v). The quality of podophyllotoxin fulfills in-house specification.

3. Pharmaceutical form

Topical solution

4. Clinical particulars
4.1 Therapeutic indications

For the topical treatment of condylomata acuminata affecting the penis or the external female genitalia.

4.2 Posology and method of administration

The affected area should be thoroughly washed with soap and water, and dried prior to application.

Warticon should be applied twice daily, morning and evening (every 12 hours) for 3 consecutive days. The treatment should then be withheld for the next 4 consecutive days.

Application to the surrounding normal tissue should be avoided.

If residual warts persist, this 3-day treatment may be repeated weekly until there is no visible wart tissue or for a total of 4 weeks of treatment.

Warticon solution should be applied to the warts with the applicator supplied with the solution.

Due to the flammable nature of Warticon solution, patients should avoid smoking or being near an open flame during application and immediately after use.

The solution should be allowed to dry before opposing skin surfaces are returned to their normal position.

Paediatric population

The safety and efficacy of topical podophyllotoxin have not been established in children under the age of 18.

4.3 Contraindications

Hypersensitivity to the active substance or any of the excipients listed in section 6.1.

Open or bleeding wounds.

Concomitant use with other podophyllotoxin containing preparations.

4.4 Special warnings and precautions for use

Where the area of treatment is greater than 4 cm2, it is recommended that treatment takes place under the direct supervision of a healthcare professional.

Avoid applying the solution to warts occurring on mucous membranes of the genital area (including the urethra, rectum and vagina).

Avoid applying the solution to surrounding healthy tissue.

Avoid contact with eyes. Should the solution accidentally come into contact with the eye, the eye should be thoroughly rinsed with water and medical advice sought.

Occlusive dressings should not be used on areas treated with the solution.

Local irritation may occur on the second or third day of application associated with the start of wart necrosis. In most cases, the reactions are mild. If severe local skin reactions occur (bleeding, swelling, excessive pain, burning, itching) the solution should be washed immediately from the treatment area with mild soap and water, treatment discontinued and the patient advised to seek medical advice.

Warticon Solution is not recommended during pregnancy or in women of childbearing potential not using contraception (see section 4.6).

It is recommended that patients refrain from sexual intercourse while treating warts with the solution and until the skin has healed. If a patient does engage in sexual intercourse, a condom must be used.

4.5 Interaction with other medicinal products and other forms of interaction

None presently known.

4.6 Fertility, pregnancy and lactation


There are limited data from the use of podophyllotoxin in pregnant women.

Although there is very limited systemic absorption from topically applied podophyllotoxin, antimitotic products such as podophyllotoxin are known to be embryotoxic. Warticon Solution is not recommended during pregnancy or in women of childbearing potential not using contraception.


There is insufficient information on the excretion of topically applied podophyllotoxin in human milk.

A risk to the newborns/infants cannot be excluded.

A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from podophyllotoxin therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.

4.7 Effects on ability to drive and use machines

None presently known.

4.8 Undesirable effects

The frequency of adverse reactions listed below is defined using the following convention: very common (≥ 1/10); common (≥ 1/100, < 1/10); uncommon (≥ 1/1,000, < 1/100); rare (≥ 1/10,000, < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

Skin and subcutaneous tissue disorders

Very Common: Skin erosion, application site irritation (including erythema, pruritus, skin burning sensation)

Post-marketing data

The following adverse drug reactions are based on post-marketing reports. Since these reports are from a population of uncertain size and are subject to confounding factors, it is not possible to reliably estimate their frequency, however in reality systemic reactions are rarely seen.

Immune system disorders

Not known: Application site hypersensitivity

Skin and subcutaneous tissue disorders

Not known: Skin ulcer, scab, skin discoloration, blister, dry skin

General disorders and administration site conditions

Not known: Application site pain, swelling, application site bleeding

Injury, poisoning and procedural complications

Not known: Caustic injury, excoriation, wound secretion

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at:

4.9 Overdose

While serious systemic effects have not been reported with the recommended dosage of topical podophyllotoxin, topical overdosage would be expected to increase systemic absorption of the drug and increase the potential for systemic effects, e.g. altered mental state and bone marrow suppression. Following oral ingestion, podophyllotoxin may also cause severe gastroenteritis.


If topical overdosage occurs, podophyllotoxin should be washed immediately from the treatment area and symptomatic and supportive therapy initiated.

Treatment of oral podophyllotoxin poisoning is symptomatic and should include supportive care.

Further management should be as clinically indicated or as recommended by the National Poisons Centre, where available.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmaco-therapeutic group: D06B B Antivirals

Podophyllotoxin is a metaphase inhibitor in dividing cells binding to at least one binding site on tubulin. Binding prevents tubulin polymerisation required for microtubule assembly. At higher concentrations podophyllotoxin also inhibits nucleoside transport through the cell membrane.

The chemotherapeutic action of podophyllotoxin is assumed to be due to inhibition of growth and the ability to invade the tissue of the viral infected cells.

5.2 Pharmacokinetic properties

Systemic absorption of podophyllotoxin after topical application of 100 mg of 0.3% cream or 100 μ L of 0.5% solution has been studied (extravaginally in 10 females, and within the preputial cavity in 10 males, each on 2 occasions separated by 8 hours). Cmax was at or below 4.7 ng/mL following all doses and Tmax ranged from 0.5 to 36 hrs; in some subjects concentrations were below the limit of detection. The Cmax and Tmax were comparable for the 0.3% cream and 0.5% solution in both males and females. It can be concluded that systemic absorption of recommended doses of podophyllotoxin cream or solution is expected to be low.

5.3 Preclinical safety data


Podophyllotoxin was not carcinogenic following dietary administration up to 0.3 mg/kg/day for 104 weeks in rats and 80 weeks in mice.

Podophyllotoxin was not mutagenic in in vitro Ames Assays, mouse lymphoma assay, and human lymphocyte metaphase assay. Podophyllotoxin showed evidence of mutagenicity in in vitro HPRT mutation assays, however results were inconsistent with regard to the dose response observed across replicate cultures. In mouse micronucleus studies, results were also inconsistent as one study did not show evidence of mutagenicity and one study did show evidence of an aneugenic effect (increased incidence of micronucleated polychromatic erythrocytes, mitotic arrest). Podophyllotoxin did induce aneuploidy in hamster oocytes.

Reproductive toxicology


In a multi-generational rat fertility and general reproductive performance study, podophyllotoxin administered orally up to 2.5 mg/kg/day had no effect on fertility in female or male rats.


Podophyllotoxin was not teratogenic in rabbits administered up to 0.5% podophyllotoxin topically or in rats administered up to 5 mg/kg/day intraperitoneally.

6. Pharmaceutical particulars
6.1 List of excipients

Phosphoric acid


Purified Water

Patent Blue V (E131)

6.2 Incompatibilities

None known.

6.3 Shelf life

36 months

6.4 Special precautions for storage

Should be stored below 25° C.

Keep container tightly closed when not in use. Contents are flammable. Keep away from fire, flame or heat. Do not leave Warticon solution in direct sunlight.

6.5 Nature and contents of container

An amber glass bottle with plastic child-proof cap. Each bottle contains 3 ml of Warticon Solution. The outer carton also includes a tube containing plastic applicators. Each loop will carry approximately 5μ l Warticon Solution.

6.6 Special precautions for disposal and other handling

No special requirements.

7. Marketing authorisation holder

Phoenix Labs

Suite 12

Bunkilla Plaza

Bracetown Business Park


County Meath


8. Marketing authorisation number(s)

PL 35104/0024

9. Date of first authorisation/renewal of the authorisation

21st June 1999 / 8th October 2003

10. Date of revision of the text

13 July 2018

Phoenix Labs
Company image
Suit 12 Bunkilla Plaza, Bracetown Business Park, Meath, Ireland
+353 1 574 2410
+353 1 8362271
Medical Information Direct Line
+353 1 574 2410
Medical Information e-mail
[email protected]
Medical Information Fax
+353 1 8362271